| NCT ID | NCT07706647 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Condition | Good Health |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-07-08 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-07-08 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to scientifically evaluate the efficacy of this oil pulling oral rinse in reducing dental plaque, gingival inflammation, gingival bleeding, and selectively reducing caries- and periodontal disease-associated bacteria compared to a marketed mouthwash and a placebo oral rinse
Eligibility Criteria
Inclusion Criteria: 1. Adult subjects aged 18-70, that are in good health. 2. Subject must have: 1. Baseline gingival inflammation (MGI) score of at least 1.80. 2. Baseline gingival bleeding (GBI) score of ≥ 1 on at least 20 sites. 3. An overnight (12 to 18 hour abstention from any oral hygiene) dental plaque (mean) score greater than 0.6 according to the RMNPI Index. 4. Have a minimum of 20 'scorable' teeth (excluding 3rd molars). 5. The subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects. Subjects will sign the Informed Consent Form. 6. The subjects should be willing to comply with the study procedure and schedule, including the follow-up visits. Exclusion Criteria: 1. Current or history of oral cavity cancer or oropharyngeal cancer. 2. Subject with destructive periodontal disease or those on antibiotic or anti-inflammatory drugs. 3. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body. 4. Pregnant or nursing by subject report. 5. Known allergic reaction to any of the study mouthwashes or any of their component. 6. Any active condition, including but not limited to advanced periodontal disease or severe gingival recession, in the oral cavity at the discretion of the investigator. 7. Any surgery or recent dental procedure in the oral cavity within 3 months prior to treatment, or before complete healing. 8. Subjects that do not brush regularly. 9. Any condition that might make it unsafe for the subject to participate in this study, at the discretion of the investigator. 10. History of allergy or hypersensitivity to mouthwash ingredients 11. Significant medical conditions, such as uncontrolled diabetes or immunosuppressive disorders 12. Use of tobacco products, including cigarettes and smokeless tobacco 13. Presence of orthodontic appliances, except for removable retainers 14. Participation in another clinical trial within the last 30 days. 15. Individuals unable to comply with study requirements, such as regular product use or scheduled visits. 16. Habitual use of alcohol or drugs that may affect compliance or oral health
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07706647 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Good Health. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07706647 currently recruiting?
Yes, NCT07706647 is actively recruiting participants. Contact the research team at amaechi@uthscsa.edu for enrollment information.
Where is the NCT07706647 trial being conducted?
This trial is being conducted at San Antonio, United States.
Who is sponsoring the NCT07706647 clinical trial?
NCT07706647 is sponsored by The University of Texas Health Science Center at San Antonio. The trial plans to enroll 120 participants.